← Leaderboards
Amar B Singh
Omaha Va Medical Center
$2,758,231
Attributed
$3,793,099
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $517.4K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,793,099 · 2
VA$0 · 3
By mechanism
R01$3,793,099 · 2
I01$0 · 2
IK6$0 · 1
Top collaborators
- David Oupicky4 shared
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularSignal TransductionColonImmuneColitisProteinsRegulationInflammatoryInflammatory Bowel DiseasesAffectTissuesEpithelialS DiseaseChronicHomeostasisColon CarcinomaTight JunctionsCitrobacter RodentiumMucous MembraneSignal PathwayInflammationEpitheliumEpithelial CellsPlay
Grant awards (23)
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Role of PTSD associated gut dysbiosis and barrier dysfunctions in promoting IBD in Veterans$0
I01 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Role of PTSD associated gut dysbiosis and barrier dysfunctions in promoting IBD in Veterans$0
I01 · FY2024 · VA · contact PI
Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease$517,434
R01 · FY2023 · DK
Claudin-3, Gut Dysbiosis and Inflammatory Bowel Disease$0
I01 · FY2023 · VA · contact PI
Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease$517,434
R01 · FY2022 · DK
Claudin-3, Gut Dysbiosis and Inflammatory Bowel Disease$0
I01 · FY2022 · VA · contact PI
Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease$517,434
R01 · FY2021 · DK
Claudin-3, Gut Dysbiosis and Inflammatory Bowel Disease$0
I01 · FY2021 · VA · contact PI
Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease$517,434
R01 · FY2020 · DK
Claudin-3, Gut Dysbiosis and Inflammatory Bowel Disease$0
I01 · FY2020 · VA · contact PI
Role of Claudin-2 in Colon Tumorigenesis$0
I01 · FY2019 · VA · contact PI
Role of Claudin-2 in Colon Tumorigenesis$0
I01 · FY2018 · VA · contact PI
Role of Claudin-2 in Colon Tumorigenesis$0
I01 · FY2017 · VA · contact PI
Role of Claudin-2 in Colon Tumorigenesis$0
I01 · FY2016 · VA · contact PI
Role of Claudin-2 in Inflammatory Diseases and Colon Cancer$327,338
R01 · FY2015 · DK · contact PI
Role of Claudin-2 in Inflammatory Diseases and Colon Cancer$315,653
R01 · FY2014 · DK · contact PI
Role of Claudin-2 in Inflammatory Diseases and Colon Cancer$23,647
R01 · FY2014 · DK · contact PI
Role of Claudin-2 in Inflammatory Diseases and Colon Cancer$327,425
R01 · FY2013 · DK · contact PI
Role of Claudin-2 in Inflammatory Diseases and Colon Cancer$339,300
R01 · FY2012 · DK · contact PI
Role of Claudin-2 in Inflammatory Diseases and Colon Cancer$390,000
R01 · FY2011 · DK · contact PI